In particular, BRAF-mutant melanoma cell lines expressing NGFRLow/AXLHigh are sensitive to SP2509, a Kdm1a inhibitor, only if not pretreated with MAPKi, probably by using the MAPK pathway to restore cell senescence [54]. This evidence concerns the gene BRAF and melanoma.